Search Results

You are looking at 81 - 90 of 1,499 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer

Emily J. Martin, Andrew R. Bruggeman, Vinit V. Nalawade, Reith R. Sarkar, Edmund M. Qiao, Brent S. Rose, and James D. Murphy

(18.6%) underwent esophageal stent placement. Table 1 contains baseline patient characteristics stratified by intervention. The 2 groups differed in terms of race, tumor histology, tumor location in the esophagus, age, and Charlson comorbidity index

Full access

Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States

Ami M. Vyas, Hilary Aroke, and Stephen Kogut

explained portion of the gap is the sum of the differences between HR-positive and HR-negative women in terms of observed characteristics weighted by the pooled regression coefficients. It is calculated by multiplying the differences in the average

Full access

Do Published Data in Trials Assessing Cancer Drugs Reflect the Real Picture of Efficacy and Safety?

Jia-Wei Lv, Yu-Pei Chen, Guan-Qun Zhou, Xu Liu, Ying Guo, Yan-Ping Mao, Jun Ma, and Ying Sun

subsequent publications, and to identify the trends of reporting quality and associated characteristics. Methods Data Source and Study Sample Data were obtained through the Aggregate Analysis of ClinicalTrials.gov (AACT) database, reflecting data

Full access

Participation of Patients With Limited English Proficiency in Gynecologic Oncology Clinical Trials

Soledad Jorge, Shatreen Masshoor, Heidi J. Gray, Elizabeth M. Swisher, and Kemi M. Doll

ethnicity patients represented 45.7% of the LEP group. Table 1. Baseline Patient Characteristics In total, 7.1.% of patients were enrolled in a clinical trial. Research participation was significantly lower among patients with LEP (2.2%) compared

Full access

EGFR-Mutated Lung Cancer With T790M-Acquired Resistance in the Brain and Histologic Transformation in the Lung

Kevin S. Scher, Juan-Sebastian Saldivar, Michael Fishbein, Alberto Marchevsky, and Karen L. Reckamp

scan after 8 weeks of erlotinib showed continued significant decrease in the right upper lobe mass and mediastinal lymphadenopathy. Table 1 Tissue Biopsy Characteristics In April 2010, the patient underwent right pneumonectomy with lymph

Full access

Role of Immunotherapy for Renal Cell Cancer in 2011

Saby George, Roberto Pili, Michael A. Carducci, and Jenny J. Kim

in search of biomarker of response to IL-2 that can be validated in subsequent studies. Table 1 Response by Baseline Characteristics The therapeutic armamentarium for metastatic RCC considerably expanded in the past several years with

Full access

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer

Matteo Lambertini, Marcello Ceppi, Richard A. Anderson, David A. Cameron, Marco Bruzzone, Maria Alice Franzoi, Claudia Massarotti, Sarra El-Abed, Yingbo Wang, Christophe Lecocq, Paolo Nuciforo, Rebecca Rolyance, Lajos Pusztai, Joohyuk Sohn, Maria Maddalena Latocca, Luca Arecco, Barbara Pistilli, Kathryn J. Ruddy, Alberto Ballestrero, Lucia Del Mastro, Fedro A. Peccatori, Ann H. Partridge, Cristina Saura, Michael Untch, Martine Piccart, Serena Di Cosimo, Evandro de Azambuja, and Isabelle Demeestere

Tumor Characteristics AMH values differed significantly at the 3 time points ( P <.001; Figure 2A ). At screening/baseline, median AMH levels were 1.29 ng/mL (IQR, 0.56–2.62 ng/mL). After 2 weeks of anti-HER2 treatment alone, a small reduction in

Full access

Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis

Kan Wu, Xu Liu, Zhihong Liu, Yiping Lu, Xianding Wang, and Xiang Li

nonmetastatic ACC using a large population-based database. In addition, we sought to identify a subset of patients with ACC who may be more likely to benefit from adjuvant radiation based on their tumor characteristics. Patients and Methods Study

Full access

“Standard Care” in Cancer Clinical Trials: An Analysis of Care Provided to Women in the Control Arms of Breast Cancer Clinical Trials

Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt, and Martin H.N. Tattersall

were extracted from ClinicalTrials.gov . Of these, 500 did not meet inclusion criteria, most because they did not use a drug intervention (80%; 400/500). Trials may have been excluded for more than one reason ( Figure 1 ). Characteristics of the 215

Full access

Serial Assessment of Urinary Incontinence in Breast Cancer Survivors Undergoing (Neo)Adjuvant Therapy

Christopher P. Chung, Carolyn Behrendt, Louise Wong, Sarah Flores, and Joanne E. Mortimer

classified according to the IIQ-7 score as major (33–99), moderate (5–29), or no impact (0). Statistical Analyses For this exploratory study, statistical significance ( P <.05) was unadjusted for multiple hypothesis testing. Demographic characteristics (age